Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Erika Isaksson Friman"'
Autor:
Kenny A Rodriguez-Wallberg, Jonas Bergh, Antonis Valachis, Per Frisk, Theodoros Foukakis, Per Ljungman, Sandra Eloranta, Hanna Pauline Nilsson, Johan Malmros, Christina Linder Stragliotto, Erika Isaksson Friman, Barbro Linderholm, Anne Andersson, Sara Harrysson, Lovisa Vennström, Helena Mörse
Publikováno v:
BMJ Open, Vol 13, Iss 12 (2023)
Background Gonadotropin-releasing hormone agonists (GnRHa) cotreatment used to transiently suppress ovarian function during chemotherapy to prevent ovarian damage and preserve female fertility is used globally but efficacy is debated. Most clinical s
Externí odkaz:
https://doaj.org/article/ba5924fc50df467589005f382b3a4808
Autor:
Emma K. Johansson, Britta Krynitz, Magnus Holmsten, Kerstin Klockhoff, Erika Isaksson Friman, Hanjing Xie
Publikováno v:
Case Reports in Oncology, Vol 11, Iss 3, Pp 751-755 (2018)
Photo-recall phenomenon is a rarely recognized adverse event of chemotherapeutic agents. The physiopathology of this entity is unclear. We have reported a 56-year old breast cancer patient with severe photo toxicity recalled 5 months after the initia
Externí odkaz:
https://doaj.org/article/2e31af1b4faa45d19beb90c3defa17d7
Autor:
Alexios Matikas, Hemming Johansson, Per Grybäck, Judith Bjöhle, Balazs Acs, Ceren Boyaci, Tobias Lekberg, Hanna Fredholm, Ellinor Elinder, Sara Margolin, Erika Isaksson-Friman, Ana Bosch, Henrik Lindman, Jamila Adra, Anne Andersson, Susanne Agartz, Mats Hellström, Ioannis Zerdes, Johan Hartman, Jonas Bergh, Thomas Hatschek, Theodoros Foukakis
Publikováno v:
Clinical Cancer Research. 29:532-540
Purpose: PREDIX HER2 is a randomized Phase II trial that compared neoadjuvant docetaxel, trastuzumab, and pertuzumab (THP) with trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Rates of pathologic complete response (pCR) did not differ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9cdd62bb9a3e1dea28fdf78f52cde05
https://doi.org/10.1158/1078-0432.ccr-22-2829
https://doi.org/10.1158/1078-0432.ccr-22-2829
Autor:
Theodoros Foukakis, Thomas Hatschek, Jonas Bergh, Johan Hartman, Ioannis Zerdes, Mats Hellström, Susanne Agartz, Anne Andersson, Jamila Adra, Henrik Lindman, Ana Bosch, Erika Isaksson-Friman, Sara Margolin, Ellinor Elinder, Hanna Fredholm, Tobias Lekberg, Ceren Boyaci, Balazs Acs, Judith Bjöhle, Per Grybäck, Hemming Johansson, Alexios Matikas
Supplementary Table S1. Representativeness of Study Participants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45a20ac4c195bec17379ecd7d458547c
https://doi.org/10.1158/1078-0432.22490726.v1
https://doi.org/10.1158/1078-0432.22490726.v1
Autor:
Theodoros Foukakis, Thomas Hatschek, Jonas Bergh, Johan Hartman, Ioannis Zerdes, Mats Hellström, Susanne Agartz, Anne Andersson, Jamila Adra, Henrik Lindman, Ana Bosch, Erika Isaksson-Friman, Sara Margolin, Ellinor Elinder, Hanna Fredholm, Tobias Lekberg, Ceren Boyaci, Balazs Acs, Judith Bjöhle, Per Grybäck, Hemming Johansson, Alexios Matikas
Supplementary Figure S1: Bland-Altman plot depicting correlation between tumor infiltrating lymphocytes assessed manually and using digital image analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::603e76a3d232f1dab5f5d078c82e890a
https://doi.org/10.1158/1078-0432.22490741
https://doi.org/10.1158/1078-0432.22490741
Autor:
Theodoros Foukakis, Thomas Hatschek, Jonas Bergh, Johan Hartman, Ioannis Zerdes, Mats Hellström, Susanne Agartz, Anne Andersson, Jamila Adra, Henrik Lindman, Ana Bosch, Erika Isaksson-Friman, Sara Margolin, Ellinor Elinder, Hanna Fredholm, Tobias Lekberg, Ceren Boyaci, Balazs Acs, Judith Bjöhle, Per Grybäck, Hemming Johansson, Alexios Matikas
Purpose:PREDIX HER2 is a randomized Phase II trial that compared neoadjuvant docetaxel, trastuzumab, and pertuzumab (THP) with trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Rates of pathologic complete response (pCR) did not differ b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33ff1c9f9cbeb17c0c74bf1a2dbe13a6
https://doi.org/10.1158/1078-0432.c.6533204.v1
https://doi.org/10.1158/1078-0432.c.6533204.v1
Autor:
Yajing Zhu, Kang Wang, Ioannis Zerdes, Alexios Matikas, Mattias Bergqvist, Ellinor Elinder, Ana Bosch, Henrik Lindman, Zakaria Einbeigi, Anne Andersson, Lena Carlsson, Ann Charlotte Dreifaldt, Erika Isaksson-Friman, Mats Hellstrom, Hemming Johansson, Jonas C. S. Bergh, Thomas Hatschek, Theodoros Foukakis
Publikováno v:
Journal of Clinical Oncology. 40:e12598-e12598
e12598 Background: Thymidine kinase 1 (TK1) plays a pivotal role in DNA synthesis and cellular proliferation. TK1 has been studied as a prognostic marker and as an early indicator of treatment response in HER2-negative early and metastatic breast can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4de9880ca3c490a61d943a53ab38c876
https://doi.org/10.1200/jco.2022.40.16_suppl.e12598
https://doi.org/10.1200/jco.2022.40.16_suppl.e12598
Autor:
Alexios Matikas, Hemming Johansson, Per Grybäck, Judith Bjöhle, Tobias Lekberg, Hanna Fredholm, Balazs Acs, Ellinor Elinder, Erika Isaksson-Friman, Susanne Agartz, Mats Hellstrom, Ioannis Zerdes, Johan Hartman, Jonas C. S. Bergh, Thomas Hatschek, Theodoros Foukakis
Publikováno v:
Journal of Clinical Oncology. 40:593-593
593 Background: Abundance of tumor infiltrating lymphocytes (TIL) is prognostic in early HER2-positive breast cancer (BC). Response to neoadjuvant therapy (NAT) according to positron emission tomography combined with computed tomography (PET-CT) has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba846576ef8a89ac1d87cdc3c27329f7
https://doi.org/10.1200/jco.2022.40.16_suppl.593
https://doi.org/10.1200/jco.2022.40.16_suppl.593
Autor:
Ellinor Elinder, Jonas Bergh, Anne Andersson, Henrik Lindman, Jamila Adra, Yvonne Brandberg, Mats Hellström, Thomas Hatschek, Hemming Johansson, Aglaia Schiza, Hanna Fredholm, Ann Charlotte Dreifaldt, Edward Azavedo, Lena M. S. Carlsson, Ioannis Zerdes, Erika Isaksson-Friman, Ana Bosch, Johan Hartman, Susanne Agartz, Gyula Pekar, Tobias Lekberg, Zakaria Einbeigi, Per Grybäck, Claudia Maes, Theodoros Foukakis, Judith Bjöhle
Publikováno v:
JAMA Oncol
Importance Trastuzumab emtansine (T-DM1) is presently approved for treatment of advanced breast cancer and after incomplete response to neoadjuvant therapy, but the potential of T-DM1 as monotherapy is so far unknown. Objective To assess pathologic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3a1e78c8a7660e59d525799668576c6
https://doi.org/10.1001/jamaoncol.2021.1932
https://doi.org/10.1001/jamaoncol.2021.1932
Autor:
Hanna Fredholm, Thomas Hatschek, Lena M. S. Carlsson, Tobias Lekberg, Yvonne Brandberg, Erika Isaksson-Friman, Judith Bjöhle, Mats Hellström, Henrik Lindman, Anne Andersson, Hemming Johansson, Zakaria Einbeigi, Ana Bosch, Jonas Bergh, Theodoros Foukakis
Publikováno v:
Journal of Clinical Oncology. 38:590-590
590 Background: Neoadjuvant therapy combining docetaxel, trastuzumab and pertuzumab (DTP) was compared to trastuzumab emtansine (T-DM1) in the randomised phase II PREDIX HER2 trial. Patients, ≥18 years with HER2 positive breast cancer, ≥20mm or w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c140d12b604ccb1aee41e58819511be
https://doi.org/10.1200/jco.2020.38.15_suppl.590
https://doi.org/10.1200/jco.2020.38.15_suppl.590